# MM-003 (NCT01311687)

> A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

No report yet. It can be ordered.

- Drugs tested: pomalidomide
- Indication: relapsed/refractory multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01311687
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Celgene
- Conditions: Multiple Myeloma
- Interventions: pomalidomide; Dexamethasone
- Enrollment: 455
- Primary outcome: Progression-free Survival (PFS) - Primary Analysis
- Primary outcome: Progression-free Survival (PFS) With a Later Cut-off Date

## Indexed commentary on MM-003 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 7 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=mm-003-nct01311687
